<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Plast Reconstr Surg Glob Open</journal-id><journal-id journal-id-type="iso-abbrev">Plast Reconstr Surg Glob Open</journal-id><journal-id journal-id-type="publisher-id">GOX</journal-id><journal-title-group><journal-title>Plastic and Reconstructive Surgery Global Open</journal-title></journal-title-group><issn pub-type="epub">2169-7574</issn><publisher><publisher-name>Wolters Kluwer Health</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5959614</article-id><article-id pub-id-type="art-access-id">00046</article-id><article-id pub-id-type="doi">10.1097/01.GOX.0000533910.02775.3f</article-id><article-categories><subj-group subj-group-type="heading"><subject>PSRC 2018 Abstract Supplement</subject><subj-group><subject>Friday, May 18</subject><subj-group><subject>Session 5: Basic/Translational Science</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Abstract 45: Beyond Antibiotics: Local Doxycycline Administration Reduces Scarring and Improves Wound Healing by Modulating Scarring Fibroblast Behavior</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>desJardins-Park</surname><given-names>Heather E.</given-names></name><degrees>AB</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Moore</surname><given-names>Alessandra L.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1,</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Murphy</surname><given-names>Matthew P.</given-names></name><degrees>MB BCh BAO MRCSI</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Irizarry</surname><given-names>Dre</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1,</xref><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Duoto</surname><given-names>Bryan</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Foster</surname><given-names>Deshka</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Ruth Ellen</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1,</xref><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Mascharak</surname><given-names>Shamik</given-names></name><degrees>BS</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Barnes</surname><given-names>Leandra</given-names></name><degrees>AB</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Marshall</surname><given-names>Clement</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Wernig</surname><given-names>Gerlinde</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Longaker</surname><given-names>Michael T.</given-names></name><degrees>MD, MBA, FACS</degrees><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label>Stanford University School of Medicine, Stanford, CA, USA</aff><aff id="aff2"><label>2</label>Brigham and Women&#x02019;s Hospital, Boston, MA, USA</aff><aff id="aff3"><label>3</label>Beth Israel Deaconess Medical Center, Boston, MA, USA</aff><aff id="aff4"><label>4</label>University of Texas Southwestern Medical Center, Dallas, TX, USA</aff></contrib-group><pub-date pub-type="collection"><month>4</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>07</day><month>5</month><year>2018</year></pub-date><volume>6</volume><issue>4 Suppl</issue><supplement>PSRC 2018 Abstract Supplement</supplement><elocation-id>35-36</elocation-id><permissions><copyright-statement>Copyright &#x000a9; 2018 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of The American Society of Plastic Surgeons. All rights reserved.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND)</ext-link>, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p></license></permissions><self-uri xlink:type="simple" xlink:href="gox-6-035.pdf"/><custom-meta-group><custom-meta><meta-name>OPEN-ACCESS</meta-name><meta-value>TRUE</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p><bold>PURPOSE:</bold> Scars can be aesthetically and functionally devastating. Novel scar treatments have the potential to impact millions of patients. Doxycycline possesses known anti-fibrotic properties. However, its role as a potential vulnerary agent has remained unexplored. We hypothesized that topically applied doxycycline would reduce scarring.</p><p><bold>METHODS:</bold> We employed a murine wounding model wherein full-thickness wounds are stented with silicone rings. This prevents wound contraction and mimics human wound healing kinetics. Antibiotic and PBS (control) solutions were injected locally into the superficial aspect of the wound base following surgery. Wounds were harvested upon complete re-epithelialization (day 15) for tensile strength testing and histologic examination. To quantify scar thickness, a blinded observer analyzed images of H&#x00026;E-stained wound cross sections in Adobe Photoshop. Three photos were analyzed per wound; for each, dermal thickness was measured at three different scar depths, for a total of nine measurements per wound. Scar thickness was calculated as the mean of these measurements. To quantify collagen branching, picrosirius red-stained images were analyzed using an algorithm in MATLAB to calculate branchpoints per 100 micron<sup>2</sup>. Bacterial colonization of wounds was assessed via wound swabbing and culture for 24 hours. Cell migration was assessed using an <italic>in vitro</italic> scratch assay. The population of &#x0201c;scarring&#x0201d; fibroblasts (<italic>Engrailed 1</italic>-positive fibroblasts, EPFs) in wounds was determined by using the same methods in <italic>En1</italic><sup><italic>Cre</italic></sup><italic>;ROSA26</italic><sup><italic>mTmG</italic></sup> mice.</p><p><bold>RESULTS:</bold> Doxycycline treatment significantly reduces scar dermal thickness by 37% compared to PBS (*<italic>P</italic>&#x0003c;0.001). Picrosirius red staining illustrates that doxycycline-treated wounds have significantly reduced picro-red, scar-like collagen (*<italic>P</italic>=0.016), and increased picro-green, favorable collagen (*<italic>P</italic>=0.016). These picro-green fibers also demonstrate significantly more branching (*<italic>P</italic>=0.032) and are less aligned, like unwounded skin collagen. Notably, ultimate tensile strength is comparable between doxycycline-treated and PBS-treated wounds (respectively: 0.462&#x02009;MPa, <italic>n</italic>=10; 0.534&#x02009;MPa, <italic>n</italic>=9; <italic>P</italic>=0.438). Bacterial colonization is not significantly altered by doxycycline treatment (<italic>P</italic>&#x0003e;0.05 at days 1, 3, 5, 7, and 9). Other tetracycline antibiotics (specifically, minocycline and tetracycline) do not decrease scar thickness. &#x0201c;Scarring&#x0201d; fibroblasts (EPFs) are reduced in doxycycline-treated wounds, demonstrated by a 33.7% decrease in GFP signal in wounds from <italic>En1</italic><sup><italic>Cre</italic></sup><italic>;ROSA26</italic><sup><italic>mTmG</italic></sup> treated mice (<italic>n</italic>=6, *<italic>P</italic>=0.021). Treating &#x0201c;scarring&#x0201d; fibroblasts (EPFs) with doxycycline <italic>in vitro</italic> significantly reduces migration rate (<italic>n</italic>=4, *<italic>P</italic>&#x0003c;0.001).</p><p><bold>CONCLUSIONS:</bold> Locally administered doxycycline reduces scarring without sacrificing scar strength. These findings may be due to increased picro-green collagen that mimics unwounded skin collagen. Our results suggest that doxycycline&#x02019;s effects are not related to antimicrobial activity. Rather, doxycycline may alter scarring fibroblast behavior during healing. Collectively, our data suggest that doxycycline may represent a novel anti-scarring therapy with the benefits of a well-established safety and dosing profile. We favor rapid transition to studies in human patients to determine whether similar effects are observed.</p><p><bold>H.E. desJardins-Park:</bold> None. <bold>A.L. Moore:</bold> None. <bold>M.P. Murphy:</bold> None. <bold>D. Irizarry:</bold> None. <bold>B. Duoto:</bold> None. <bold>D. Foster:</bold> None. <bold>R.E. Jones:</bold> None. <bold>S. Mascharak:</bold> None. <bold>L. Barnes:</bold> None. <bold>C. Marshall:</bold> None. <bold>G. Wernig:</bold> None. <bold>M.T. Longaker:</bold> None.</p></body></article>